

FAST Translational Research Symposium and Angelman Syndrome Biomarker and Outcome Measure Consortium (ABOM)

Thursday, December 1, 2022
Diplomat Hotel, Miami Florida
Abstract submissions due October 1, 2022
Notification: October 15, 2022

RSVP for attendance by Nov 1, 2022
Limited attendance to 200 guests

The Foundation for Angelman Syndrome Therapeutics invites you to attend the annual **FAST Translational Research Symposium and ABOM Scientific Meeting**, which will be held **live on Thursday, December 1, 2022 in Hollywood, Florida**. This event is planned to be both in-person and virtual in a hybrid mode. We would like for you to reserve space on your calendar for this incredible event.

You can join us to listen and participate in the most up-to-date research, from proof-of-concept in vitro and in vivo work to clinical trial updates, and advances in clinical endpoints and biomarkers. This Symposium is designed for scientists, industry partners and medical professionals. We invite the participation of investigators whose research could inform or impact various therapeutic platforms in Angelman syndrome, as well as those in early stages of development. We expect the interdisciplinary attendees will represent scientists, clinicians, regulatory experts, and pharmaceutical/industry representatives. This symposium is designed to foster collaboration and scientific/clinical advancements, and be confidential and supportive. The goal of this Symposium is to discuss progress and challenges towards potential therapies in AS, inspire thoughtful discussions on critical issues, and foster networking and collaborations in a professional environment.

This symposium will be closed to only registered participants with a limitation of only 200 guests. There will be **no recording, pictures, distribution or publication of any abstracts or slides unless the presenter approves to do so**. This is meant to be a safe place to share confidential information in order to encourage advances in the science of translational research for Angelman syndrome.

For those abstracts not chosen for oral presentation we will have poster opportunities as well. **FAST will sponsor the cost of travel, hotel and gala tickets to all speakers chosen to present an abstract** (unless this is covered in FAST funded grants for this year).

Oral presentations and a single slide brief communications/posters will be presented, as well as some round table discussions. **If you are interested in submitting an abstract**

the deadline is October 1, 2022. The submission should be no longer than 250 words. Please RSVP and submit abstracts to Allyson Berent (Allyson.berent@gmail.com) and Dave Segal (disegal@ucdavis.edu). Please contact us with any questions about the event. We are so excited to “see” you all in December, and continue to make progress toward meaningful therapeutics for those living with Angelman syndrome.

With kindest regards,

David J Segal, PhD

Professor and Co-Chair of the Integrative Genetics and Genomics graduate group
Genome Center, Biochemistry and Molecular Medicine, Pharmacology, and MIND Institute
University of California, Davis

Allyson Berent, DVM, DACVIM

Chief Science Officer, Foundation for Angelman Syndrome Therapeutics
Chief Operating Officer, GeneTx Biotherapeutics
Director, Angelman Syndrome Biomarker and Outcome Measure Consortium
Co-Director, International Angelman Syndrome Research Council (INSYNC-AS)
Director of Interventional Endoscopy/Internal Medicine, The Animal Medical Center